Shanghai Haohai Biological Technology Co., Ltd. (together with its subsidiaries hereinafter referred to as "Haohai ") is a technology innovative enterprise that utilizes biomedical material technology and genetic engineering technology for the research, development, production, and sales of medical devices and pharmaceuticals. Haohai is dedicated to providing innovative medical products to the market through technological innovation and transformation, integration of domestic and international resources, and large-scale production, gradually realizing the import substitution of relevant pharmaceutical products and becoming a leading enterprise in the field of biomedical materials. Haohai was listed on the main board of the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market on April 30, 2015, and October 30, 2019, respectively, making it the first "Hong Kong Stock + SSE STAR Market" biopharmaceutical listed company in China.
After more than a decade of continuous innovation and industrial integration, as of 2023, we have completed the industry restructuring of biomedical materials represented by artificial intraocular lenses, medical sodium hyaluronate/hyaluronic acid, medical chitosan, etc. We have achieved the industrialization of human epidermal growth factor, an innovative gene engineering drug (national class I new drug), and gained leading advantages in four major business areas including ophthalmology, medical aesthetics& wound care, orthopedics, anti-adhesion& hemostasis.
According to a series of reports released by Guangzhou Biaodian Pharmaceutical Information Co., Ltd., as of the year 2023, Haohai has ranked the China market share leader in ophthalmic viscoelastic agents and surgical anti-adhesion agents for 17 consecutive years, and ranked first in China’s market of orthopedic joint cavity viscoelastic supplements for 10 consecutive years. It has also maintained its position as the second largest manufacturer of topical human epidermal growth factor in China for 10 consecutive years. Haohai is a major supplier in China’s artificial intraocular lens market and one of the globally renowned independent ophthalmic material manufacturers.
Haohai has two products received the National Science and Technology Progress Award (Second Prize), and established two national R&D platforms of national enterprise technology center and national postdoctoral research workstation, as well as a number of provincial technology and R&D transformation platforms and a Shanghai academician expert workstation. It also established global R&D system covering China, the United States, the United Kingdom, France and Israel. By the end of 2023, Haohai had undertaken 12 national projects from the Ministry of Science and Technology and over 40 scientific and technological projects from Shanghai government. The company has applied for more than 500 patents, including over 100 granted invention patents and dozens of international invention patents (covering the United States, the European Union, Japan, South Korea, Spain, and other countries and regions), and drafted or participated in the revision of over 10 industry standards for biomaterials and medical devices.
Haohai aims to improve the health of the Chinese people and facilitate patient recovery, with a corporate strategic focus on differentiated development. It remains committed to the rapidly evolving fields of ophthalmology, medical aesthetics & wound care, orthopedics, and surgery. Emphasizing scientific innovation and the commercialization of technological advancements, Haohai aims to position itself as a leading domestic and globally recognized enterprise group in the biomaterial sector by refining its product portfolio, optimizing industry integration, and enhancing professional services and brand recognition.
Company Overview